Filing Analysis
AIxCrypto Holdings, Inc. entered into a common shares purchase agreement with Gold King Arthur Holding Limited for a private placement of up to $50 million in common stock. The agreement is structured as a variable-price equity line, allowing the company to draw funds at a discount to the VWAP.
🚩 Red Flags
- Toxic pricing structure: The 7% discount to the lowest 3-day VWAP is characteristic of 'death spiral' financing, which can lead to massive dilution.
- Significant dilution potential: The offering allows for up to $50M in shares, which is substantial for a micro-cap company.
- Upfront cash drain: Payment of a $100,000 non-refundable fee before receiving any capital.
- Dependence on shareholder approval: The company must seek approval to exceed the 19.99% cap, indicating a high volume of potential issuance.
📋 Key Facts
- Agreement date: June 16, 2026
- Maximum offering amount: $50,000,000 or 19.99% of voting power (Exchange Cap), whichever is lesser, unless shareholder approval is obtained.
- Pricing: 93% of the lowest daily VWAP over the three consecutive trading days preceding the purchase date.
- Fees: Company paid a $100,000 non-refundable upfront fee; Purchaser retains a 3.0% draw fee on each purchase.
- Registration: Company must file a Form S-1 registration statement within 45 days for the resale of shares.
- Purchaser: Gold King Arthur Holding Limited, a Hong Kong limited liability company.
AIxCrypto Holdings (AIXC) announced a massive executive overhaul on May 21, 2026, including the immediate resignation of the Co-CEO, President, and CFO/Director, alongside the appointment of new leadership and the discontinuation of its legacy biotechnology business segment.
🚩 Red Flags
- Mass exodus of top leadership: Co-CEO, President, and CFO all resigned on the same day (May 21).
- Related-party transaction/influence: New Director Jerry Wang is the nephew of the CEO of the majority shareholder.
- Strategic pivot/failure: Discontinuation of the legacy biotechnology business segment indicates a failure of previous strategic direction.
- Multiple 8-K items (5.02 and 8.01) in a single filing, which is a red flag escalator for severity.
- Significant loss of institutional knowledge and leadership stability during a business wind-down.
📋 Key Facts
- Kevin Richardson II (Co-CEO and Director) resigned effective immediately on May 21, 2026.
- Campbell Becher (President) resigned effective immediately on May 21, 2026.
- Koti Meka (CFO and Director) resigned as Director immediately and as CFO effective June 20, 2026.
- Jie (Jay) Sheng appointed as President and CFO effective June 21, 2026; annual base salary $400,000, bonus up to $200,000.
- Jerry Wang appointed as Director; he is the nephew of Mr. Yueting Jia, the CEO of the Company's majority shareholder.
- Chen Shi appointed as Independent Director.
- The Board approved the discontinuation and structured wind-down of the legacy biotechnology business segment on May 21, 2026.
AIxCrypto Holdings (AIXC) is selling a 'Note Package' totaling over $6.5 million in principal and accrued interest from Marizyme, Inc. to CABG Acquisition Corp. for a nominal $100,000 in cash, a 4.99% equity stake in the buyer, and potential future royalties.
🚩 Red Flags
- Extreme valuation gap: Selling ~$6.5M in face-value debt for only $100k in immediate cash (a 98%+ haircut).
- The 18% interest rate on the original note indicates the debtor (Marizyme) was likely in a distressed financial state.
- The transaction suggests a total or near-total impairment of the Marizyme assets.
- Corporate identity change: The filing notes AIXC is the successor to Qualigen Therapeutics, Inc., often a sign of a 'clean-up' or pivot after failure.
📋 Key Facts
- Sold a secured demand promissory note with a principal amount of approximately $4,771,142 and an 18% interest rate.
- Sold a $1,750,000 Co-Development Note related to the commercial success of the DuraGraft product.
- Upfront cash consideration is only $100,000.
- AIXC receives a 4.99% membership interest in CABG Acquisition Corp. with preemptive and registration rights.
- AIXC is entitled to 10% royalty payments on cumulative Net Revenue exceeding $20,000,000.
- The company was previously known as Qualigen Therapeutics, Inc.
AIxCrypto Holdings, Inc. announced its financial and operational results for the first quarter ended March 31, 2026. The company also conducted an investor webcast to discuss these results and provide general corporate updates.
📋 Key Facts
- Financial results cover the three months ended March 31, 2026.
- The announcement was made via a press release and an investor presentation on May 11, 2026.
- An investor webcast was held on May 11, 2026, to discuss results and corporate developments.
- The report was signed by Koti Meka, Chief Financial Officer.
AIxCrypto Holdings amended its investment agreement with GKA to increase its commitment to Faraday Future (FFAI) to $12 million, primarily through Series C Convertible Preferred Stock. The transaction involves a complex entrusted management structure and includes warrants contingent on FFAI vehicle delivery milestones.
🚩 Red Flags
- Complex 'entrusted' investment structure where a third party (GKA) holds and manages the assets for the company.
- Removal of protective security (share charge) on the investment manager's (Song Wang) interest in GKA.
- Highly dilutive 'Alternative Conversion Price' features, allowing conversion at the lower of fixed or market prices.
- Significant capital concentration in Faraday Future (FFAI), a company with a history of financial volatility.
📋 Key Facts
- Increased investment commitment from $10 million to $12 million via GOLD KING ARTHUR HOLDING LIMITED (GKA).
- $11.5 million of the investment is allocated to Series C Convertible Preferred Stock of Faraday Future (FFAI).
- Conversion price for preferred stock is $0.26, with an 'Alternative Conversion Price' floor as low as $0.13.
- A $2 million loan at 10% interest was provided to FFAI and subsequently converted into the equity subscription.
- Warrant for 1,000,000 shares at $1.50 exercise price is contingent on the delivery of the 500th FX Super One vehicle.
- Amendments removed a share charge on GKA shares held by Song Wang and carved out his equity from a call option.
AIxCrypto Holdings, Inc. announced its fiscal year 2025 financial and operational results and provided a corporate update via a press release and investor webcast on March 24, 2026.
📋 Key Facts
- Announced financial results for the fiscal year ended December 31, 2025
- Held an investor webcast on March 24, 2026, to discuss results and corporate developments
- Furnished a press release (Exhibit 99.1) and investor presentation (Exhibit 99.2)
- The filing was made under Items 2.02 (Results of Operations) and 7.01 (Regulation FD Disclosure)
AIxCrypto Holdings, Inc. issued a press release on February 23, 2026, providing a corporate update on business highlights and strategic initiatives planned for 2026.
📋 Key Facts
- The company issued a press release on February 23, 2026, regarding business highlights and 2026 strategic execution.
- The filing was made under Item 8.01 (Other Events) and includes the press release as Exhibit 99.1.
- AIxCrypto Holdings is a Nasdaq-listed company (AIXC) based in Carlsbad, California.
- The report was signed by Chief Financial Officer Koti Meka on February 27, 2026.